Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as...
Saved in:
Main Authors: | Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/a5cb9fa2bdcc4009ba782630d37a3d2e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
by: Hidayati Husainy Hasbullah, et al.
Published: (2021) -
KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
by: Olga I. Brovkina, et al.
Published: (2021) -
Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
by: M. I. Sekacheva, et al.
Published: (2020) -
Oncogenic KRAS: Signaling and Drug Resistance
by: Hyeon Jin Kim, et al.
Published: (2021) -
Recent insights into nanotechnology development for detection and treatment of colorectal cancer
by: Viswanath B, et al.
Published: (2016)